Novocure Ltd (NVCR) Stock Analysis & Investment Frameworks
Novocure Ltd (NVCR) stock analysis on Invetso. Review Novocure Ltd’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Novocure Ltd Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Medical - Devices
- Country: CH
Novocure Ltd Key Financial Metrics
- Market Cap: $1.76B
- Revenue: $655.35M
- ROE: -44.00%
- ROIC: -26.15%
- Dividend Yield: N/A
About Novocure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Novocure Ltd Investment Frameworks
Invetso analyzes Novocure Ltd (NVCR) across the following frameworks:
- Novocure Ltd 10Y Growth Potential
- Novocure Ltd Scenario Analysis
- Novocure Ltd Risks & Opportunities
- Novocure Ltd Economic Moat
- Novocure Ltd Business Model
- Novocure Ltd Management
- Novocure Ltd SWOT Analysis
- Novocure Ltd Porter's 5 Forces
- Novocure Ltd PESTLE Analysis
- Novocure Ltd ESG Analysis